CN115569164A - 一种解酒降脂的中药复方制剂及其制备方法与应用 - Google Patents
一种解酒降脂的中药复方制剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN115569164A CN115569164A CN202110756154.3A CN202110756154A CN115569164A CN 115569164 A CN115569164 A CN 115569164A CN 202110756154 A CN202110756154 A CN 202110756154A CN 115569164 A CN115569164 A CN 115569164A
- Authority
- CN
- China
- Prior art keywords
- preparation
- medicine
- application
- compound preparation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 94
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 230000000694 effects Effects 0.000 title abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 50
- 241000208340 Araliaceae Species 0.000 claims description 41
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 41
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 41
- 235000008434 ginseng Nutrition 0.000 claims description 41
- 239000000843 powder Substances 0.000 claims description 39
- 238000002156 mixing Methods 0.000 claims description 32
- 244000046146 Pueraria lobata Species 0.000 claims description 25
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 25
- 238000010298 pulverizing process Methods 0.000 claims description 25
- 208000007848 Alcoholism Diseases 0.000 claims description 24
- 235000021551 crystal sugar Nutrition 0.000 claims description 22
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 20
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 20
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 20
- 201000007930 alcohol dependence Diseases 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
- 241000628997 Flos Species 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 230000005484 gravity Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 229940023488 pill Drugs 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 241000411851 herbal medicine Species 0.000 claims description 7
- 241000219780 Pueraria Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 4
- 206010001605 Alcohol poisoning Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 206010029350 Neurotoxicity Diseases 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 231100000228 neurotoxicity Toxicity 0.000 claims description 2
- 230000007135 neurotoxicity Effects 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 28
- 230000007812 deficiency Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 238000007873 sieving Methods 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 3
- 241000244186 Ascaris Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药制剂技术领域，且公开了一种解酒降脂的中药复方制剂及其制备方法与应用，包括葛花、乌梅、薄荷和人参，葛花、乌梅、薄荷、人参和冰糖通过制备形成复方制剂，通过由葛花、乌梅、薄荷和人参或者葛根、乌梅、薄荷和人参构成，加有或者不加有冰糖，冰糖用于调味，葛花药性平稳，味甘，入脾、胃经，能够醒脾的作用，葛根，性甘、辛，凉，有解肌退热，透疹，生津止渴，升阳止泻之功，常用于表证发热，而乌梅性平、味酸，入肝、脾、肺、大肠经，具有敛肺、涩肠、生津、安蛔的功效，方中人参大补元气、补脾益肺、生津、安神定志，整个方子具有去热化湿，补气醒神的效果，可以治疗这些疾病，达到了醒酒降低血脂以及减肥的功能。
Description
技术领域
本发明涉及中药制剂技术领域，具体为一种解酒降脂的中药复方制剂及其制备方法与应用。
背景技术
酒在我国有着悠久的历史，并已形成一种酒文化，但过量饮酒则会有害健康，影响人们的生活；
高脂血症是指血脂水平过高，可直接引起一些严重危害人体健康的疾病，如动脉粥样硬化、冠心病、胰腺炎等。临床表现主要是脂质在真皮内沉积所引起的黄色瘤和脂质在血管内皮沉积所引起的动脉硬化；
肥胖是指一定程度的明显超重与脂肪层过厚，是体内脂肪，尤其是甘油三酯积聚过多而导致的一种状态。它不是指单纯的体重增加，而是体内脂肪组织积蓄过剩的状态。
可见，亟需一种解酒降脂的中药复方制剂，用于解决上述背景技术中提到的各种症状。
发明内容
(一)解决的技术问题
针对现有技术的不足，本发明提供了一种解酒降脂的中药复方制剂及其制备方法，具备醒酒降低血脂和减肥等优点，解决了上述背景技术中提到的醉酒和高血脂对人体带来危害的问题。
(二)技术方案
为实现上述目的，本发明提供如下技术方案：一种解酒降脂的中药复方制剂，包括葛花、乌梅、薄荷和人参，葛花、乌梅、薄荷、人参和冰糖通过制备形成复方制剂。
优选的，葛花1-60克、乌梅1-60克、薄荷1-30克、人参1-18克、冰糖0-30克。
优选的，葛根10-40克、乌梅10-40克、薄荷5-20克、人参3-12克、冰糖0-30克。
优选的，制备成的复方药剂分为固体制剂、膏状制剂、液体制剂，其中固体制剂为袋装、粉状、胶囊、颗粒、含片、片剂、滴丸，膏状制剂包括由这四种中药煎制或者熬制的，或者其各种提取物所制成的膏状制剂，液体制剂为煎制的，提取的物质所制成的各种口服液或擦剂。
一种解酒降脂的中药复方制剂的制备方法，包括以下步骤：
(1)将人参、冰糖碎成细粉；
(2)分别将薄荷、葛花、乌梅粉碎成粗粉，然后分别用药材重量5-10倍量的30～50％(w/w)乙醇或水提取2-3次，每次1-2小时，滤过，合并滤液，滤液浓缩成比重1.2-1.35(80～90℃)稠膏或者使用这些药物的提取物；
(3)将上述稠膏合并或者它们的提取物混合，再加入人参和冰糖细粉，混匀，干燥，粉碎成粒径细粉，加入适量药用辅料制成固体制剂、液体制剂。
一种解酒降脂的中药复方制剂的应用，本中药复方应用于以下方面：
中药复方制剂在制备防治急性酒精中毒药物中的应用；
中药复方制剂在制备防治慢性性酒精中毒药物中的应用；
中药复方制剂在制备防治慢性酒精中毒性脂肪肝药物中的应用；
中药复方制剂在制备治疗慢性酒精中毒导致神经中毒药物中的应用；
中药复方制剂在制备预防治疗高血脂药物中的应用；
中药复方制剂在制备预防治疗脂肪肝药物中的应用；
中药复方制剂在制备治疗肥胖中的应用；
中药复方制剂在制备降低体重中的应用。
与现有技术相比，本发明提供了一种解酒降脂的中药复方制剂，具备以下有益效果：
该解酒降脂的中药复方制剂，通过由葛花、乌梅、薄荷和人参或者葛根、乌梅、薄荷和人参构成，加有或者不加有冰糖，冰糖用于调味，葛花药性平稳，味甘，入脾、胃经，能够醒脾的作用，葛根，性甘、辛，凉，有解肌退热，透疹，生津止渴，升阳止泻之功，常用于表证发热，项背强痛，麻疹不透，热病口渴，阴虚消渴，热泻热痢，脾虚泄泻的作用，而乌梅性平、味酸，入肝、脾、肺、大肠经，具有敛肺、涩肠、生津、安蛔的功效，可以用于治疗肺阴虚长久咳嗽、虚热消渴、久泻久痢等疾病，味酸能生津止渴，所以可以治疗烦渴等症状，方中薄荷薄荷味辛、性凉，具有疏散风热的作用，方中人参大补元气、补脾益肺、生津、安神定志，整个方子具有去热化湿，补气醒神的效果，可以治疗这些疾病，达到了醒酒降低血脂以及减肥的功能。
具体实施方式
下面将结合本发明实施例对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
具体实施方式一
本实施方式为一种解酒降脂的中药复方制剂的实施方式。
一种解酒降脂的中药复方制剂，包括葛花、乌梅、薄荷和人参，葛花、乌梅、薄荷、人参和冰糖通过制备形成复方制剂。
根据上述配置方法，制备成的复方药剂分为固体制剂、膏状制剂、液体制剂，其中固体制剂为袋装、粉状、胶囊、颗粒、含片、片剂、滴丸，膏状制剂包括由这四种中药煎制或者熬制的，或者其各种提取物所制成的膏状制剂，液体制剂为煎制的，提取的物质所制成的各种口服液或擦剂
具体实施方式二
本实施方式为一种解酒降脂的中药复方制剂的制备方法的实施方式。
一种解酒降脂的中药复方制剂的制备方法，包括以下配方及步骤：
1.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10
制备方法：将各份重要浸泡30分钟，倒去水分，然后加入10-20倍的清水，中火煎煮60分钟，收取药液，过滤，装瓶待用。
2.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10。
制备方法：
(1)人参和冰糖碎成细粉；
(2)葛花或葛根、乌梅、薄荷分别粉碎成粗粉，分别用药材重量5倍量的40％(w/w)乙醇提取2次；每次2小时，滤过，合并滤液，滤液浓缩成比重1.3(80～90℃)稠膏；
(3)将上述稠膏合并，加入人参和冰糖细粉，混匀，干燥，粉碎成细粉，加混匀，过筛，用水泛丸，低温干燥，打光，阴干。
3.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10。
制备方法：
(1)人参和冰糖碎成细粉；
(2)葛花或葛根、乌梅、薄荷分别粉碎成粗粉，分别用药材重量5倍量的40％(w/w)乙醇提取2次；每次2小时，滤过，合并滤液，滤液浓缩成比重1.3(80～90℃)稠膏；
(3)将上述稠膏合并，加入人参和冰糖细粉，混匀，干燥，粉碎成细粉，混匀，过筛，再与415g融熔状态(100℃左右)的聚乙二醇－6000混匀(徐徐加入药粉，不断搅拌)，待温度降至80℃左右时，采用丸重40mg单头或多头滴丸机滴入冷却剂中(液体石蜡或硅油)，收集冷却剂中的滴丸，经擦拭，凉干，选滴丸，装瓶。
4.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10。
制备方法：
(1)人参和冰糖碎成细粉；
(2)葛花或葛根、乌梅、薄荷分别粉碎成粗粉，分别用药材重量5倍量的40％(w/w)乙醇提取2次；每次2小时，滤过，合并滤液，滤液浓缩成比重1.3(80～90℃)稠膏；
(3)将上述稠膏合并，加入人参和冰糖细粉，混匀，干燥，粉碎成细粉，混匀，过筛，混匀，过筛，再与淀粉300g混合均匀，用淀粉浆(取淀粉220g用水制成淀粉浆)制颗粒，过筛，干燥，装胶囊。
5.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10。
制备方法：
(1)人参和冰糖碎成细粉；
(2)葛花或葛根、乌梅、薄荷分别粉碎成粗粉，分别用药材重量5倍量的40％(w/w)乙醇提取2次；每次2小时，滤过，合并滤液，滤液浓缩成比重1.3(80～90℃)稠膏；
(3)将上述稠膏合并，加入人参和冰糖细粉，混匀，干燥，粉碎成细粉，混匀，过筛，加入100g羧甲基纤维素钠，180g糖，混匀，用30％乙醇制颗粒，过筛，干燥，装袋。
6.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10。
制备方法：
(1)人参和冰糖碎成细粉；
(2)葛花或葛根、乌梅、薄荷分别粉碎成粗粉，分别用药材重量5倍量的40％(w/w)乙醇提取2次；每次2小时，滤过，合并滤液，滤液浓缩成比重1.3(80～90℃)稠膏；
(3)将上述稠膏合并，加入人参和冰糖细粉，混匀，干燥，粉碎成细粉，混匀，过筛，过筛，再与淀粉340g混合均匀，用淀粉浆(取淀粉210g用水制成淀粉浆)制颗粒，过筛，干燥，加6‰硬脂酸镁,混匀,压制成片,包薄膜衣即得。
7.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10。
制备方法：
(1)人参和冰糖碎成细粉；
(2)葛花或葛根、乌梅、薄荷分别粉碎成粗粉，分别用药材重量5倍量的40％(w/w)乙醇提取2次；每次2小时，滤过，合并滤液，滤液浓缩成比重1.3(80～90℃)稠膏；
(3)将上述稠膏合并，加入人参和冰糖细粉，混匀，干燥，粉碎成细粉，混匀，将淀粉和纤维素过筛，并充分混合，将聚乙烯吡咯烷酮溶液与上述的粉混合，过筛，制得湿颗粒于50-60℃干燥，将羧甲基淀粉钠盐，硬脂酸镁和滑石粉预先过筛，然后加入到上述的颗粒中压片。
8.组方：葛花或葛根20、乌梅20、薄荷10、人参6、冰糖10。
制备方法：
(1)人参和冰糖碎成细粉；
(2)葛花或葛根、乌梅、薄荷分别粉碎成粗粉，分别用药材重量5倍量的40％(w/w)乙醇提取2次；每次2小时，滤过，合并滤液，滤液浓缩成比重1.3(80～90℃)稠膏；
(3)将上述稠膏合并，加入人参和冰糖细粉，混匀，干燥，粉碎成细粉，混匀，加入苯甲酸钠适量，再加水调整至总量，搅拌均匀经高速离心机分离得澄清液，加入矫味剂适量搅拌后静置48小时，过滤，得棕褐色粘稠液体，灌装，经100℃流通蒸汽灭菌，制成口服液。
具体实施方式三
本实施方式为本发明配方方解的实施方式。
葛花：味甘，性凉，用于伤酒烦热口渴，头痛头晕，脘腹胀满，呕逆吐酸，不思饮食，吐血，肠风下血，药食两用。
葛根：性凉味甘辛，有解表退热，生津、透疹、升阳止泻等多种功能，《本草纲目》中这样记载：“葛，性甘、辛、平、无毒，主治：消渴、身大热、呕吐、诸弊，起阴气，解诸毒”现代研究表明具有提高肝细胞的再生能力，促进新陈代谢，加强肝脏解毒功能，防止酒精对肝脏的损伤、对高血脂形成的冠状动脉硬化，通过改善心肌缺血状态，防治冠心病、心绞痛、心肌梗塞等心血管疾病的功效。药食两用。
薄荷：味辛，性凉；疏散风热，清利头目，利咽透疹，疏肝行气，可以治疗外感风热，头痛，咽喉肿痛，食滞气胀，口疮，牙痛，疮疥，瘾疹，温病初起，风疹瘙痒，肝郁气滞，胸闷胁痛，药食两用。
乌梅：酸、涩，平。归肝、脾、肺、大肠经，敛肺，涩肠，生津，安蛔，用于肺虚久咳，久泻久痢，虚热消渴，蛔厥呕吐腹痛，现代药理研究表明有利胆作用；抗过敏作用，药食两用。
人参：、人参味甘、微苦，性微温，归脾、肺、心、肾经，气雄体润，升多于降；具有补气固脱，健脾益肺，宁心益智，养血生津的功效，人参主治大病、久病、失血、脱液所致元气欲脱，神疲脉微；脾气不足之食少倦怠，呕吐泄泻；肺气虚弱之气短喘促，咳嗽无力；心气虚衰之失眠多梦，惊悸健忘，体虚多汗；津亏之口渴，消渴；血虚之萎黄，眩晕；肾虚阳萎，尿频，气虚外感。药食两用。
冰糖：润肺、止咳、清痰、和去火的功效，药食两用。
具体实施方式四
本实施方式为药理实验的实施方式。
一)解酒实验
1材料及方法
1.1材料
解酒复方：葛花、乌梅、薄荷和人参购买自河南省禹州市中药材市场获得，四者比例是4:4:2:1配方，加入去离子水覆盖，浸泡30分钟，煎煮2h。过滤后收集滤液，再加入离子水煎煮1.5h。合并滤液进行蒸发制成膏剂，生药含量为1g/ml。
乙醇：红星二锅头，含50％乙醇。
昆明小鼠40只,体重(20±2)g。
1.2方法：将购买的雄性小鼠分成随机分成5组，即空白组、模型组、解酒配方低、中和高剂量组，共5组，每组10只。实验前禁食，除空白组外，其他各组给予酒精(53.6°红星二锅头)0.14ml/10g，处于醉酒状态。经过30min后，其中三组分别给予ZGY-1，剂量分别是0.05、0.1和0.2ml/10g三个剂量，灌胃，每天一次，其他组给予等体积的生理盐水。灌酒后计时，记录小鼠醉酒时间和小鼠的醉酒只数。数据分析计量资料组间差异用t检验,计数资料两样本率比较采用Fisher确切概率法检验,以P<0.05为差异有统计学意义。
2结果
由表1可知，和模型组相比，使用ZGY-1药物后，低、中、高剂量各组的醉酒小鼠和死亡小鼠都明显下降(P＜0.05)，都没有出现死亡现象。同样，药物各剂量组小鼠的苏醒时间则分别与模型组相比，显著缩短了48.22％、74.73％、80.66％和116.30％(P＜0.05)。有表2可知，药物高剂量组的效果最好(P＜0.05)。结果表明，给酒30min后，给予ZGY-1，能够在一定程度上缩短小鼠的醉酒时间，具有一定的解酒效果。
表1中药配方对小鼠苏醒时间的影响
*P＜0.05
二)小鼠防醉试验
1.方法将购买的雄性小鼠分成随机分成5组，即空白组、模型组、解酒配方低、中和高剂量组，共5组，每组10只。空白以及模型组每只给予0.1ml/10gNS，ZGY-1低、中和高剂量组分别为0.05、0.1和0.2ml/10g,灌胃每天一次，30min后，除空白对照外，其余各组给予0.14ml/10g53.6°红星二锅头。并立刻计时，观察并记录记录小鼠醉酒时间、睡眠时间和各组小鼠的醉酒只数。
2.结果：
与模型组相比，ZGY-1高、中、低各剂量组的醉酒小鼠数和死亡小鼠数都显著下降，并且各组均无小鼠死亡出现(P＜0.05)。与模型组相比，用药各剂量组小鼠的醉酒麻醉持续时间随着药物剂量的增加而呈现明显缩短，并具有统计学差异(P<0.05)。这些数据表明表明，给酒前0.5h先给予一定量的药物能够预防小鼠进入醉酒时间，具有一定的防醉效果。结果参见表2。
表2中药配方对小鼠醉酒时间的影响
*P＜0.05**P<0.01
三).对高血脂动物模型的降脂作用
1实验动物：SPF级雄性昆明种小鼠，6周龄。所有实验动物处于同一环境，自由采食、采水，室内环境温度为(23±2)℃，相对湿度为(50±5)％，12h明暗循环。适应性饲养1周后按体重将小鼠随机分为5组，其中包括空白组、高血脂模型组，预防治疗组，高剂量组，中剂量组(相当于人使用的剂量)和低剂量组，2倍组间距。预防组一开始给与高脂饮食的时候就开始喂药。治疗组等复制出高脂血症时才给予药物治疗。实验结束的时候，禁食12小时，取血检测总胆固醇(TC)，总甘油三酯(TG)，高密度脂蛋白(HDL)和低密度脂蛋白(LDL)。
2用药方法：按上述分组情况，制作好模型后，每天一次对小鼠灌胃药物低剂量0.05ml/10g、中剂量0.1ml/10g和高剂量0.2ml/10g，预防组剂量和中剂量组一样空白组与高脂模型组灌胃生理盐水，连续8周，检测其体重
3实验结果：
3.1.小鼠体重的变化
将各组间的体重进行比较，如表3所示。从第2周开始，高脂模型组小鼠体重显著高于正常组，模型建成。高脂饮食小鼠连续灌胃1周后体重开始显著降低，连续灌胃3周后体重开始显著降低(P<0.05)。可见，药物能够显著抑制高脂饮食引起的小鼠体重增加。而且预防组的体重下降更多。
表3.药物对体重的影响
*P<0.05
3.2血清脂质变化情况：
由表4可知，在整个实验过程中，高脂饮食小鼠的血清TG、TC、LDL-c水平总体呈上升趋势，而HDL-c水平呈下降趋势，即高脂饮食能够引起小鼠血浆脂质的紊乱。通过用药灌胃处理，用药组小鼠的TC和TG水平的升高都得到一定抑制。
表4药物高脂饮食小鼠血脂的改善作用
*P<0.05
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物定。
Claims (6)
1.一种解酒降脂的中药复方制剂，包括葛花、乌梅、薄荷和人参，其特征在于：葛花、乌梅、薄荷、人参和冰糖通过制备形成复方制剂。
2.根据权利要求1所述的一种解酒降脂的中药复方制剂，其特征在于：葛花1-60克、乌梅1-60克、薄荷1-30克、人参1-18克、冰糖0-30克。
3.根据权利要求1所述的一种解酒降脂的中药复方制剂，其特征在于：葛根10-40克、乌梅10-40克、薄荷5-20克、人参3-12克、冰糖0-30克。
4.根据权利要求1所述的一种解酒降脂的中药复方制剂，其特征在于：制备成的复方药剂分为固体制剂、膏状制剂、液体制剂，其中固体制剂为袋装、粉状、胶囊、颗粒、含片、片剂、滴丸，膏状制剂包括由这四种中药煎制或者熬制的，或者其各种提取物所制成的膏状制剂，液体制剂为煎制的，提取的物质所制成的各种口服液或擦剂。
5.一种解酒降脂的中药复方制剂的制备方法，其特征在于：包括以下步骤：
(1)将人参、冰糖碎成细粉；
(2)分别将薄荷、葛花、乌梅粉碎成粗粉，然后分别用药材重量5-10倍量的30～50％(w/w)乙醇或水提取2-3次，每次1-2小时，滤过，合并滤液，滤液浓缩成比重1.2-1.35(80～90℃)稠膏或者使用这些药物的提取物；
(3)将上述稠膏合并或者它们的提取物混合，再加入人参和冰糖细粉，混匀，干燥，粉碎成粒径细粉，加入适量药用辅料制成固体制剂、液体制剂。
6.一种解酒降脂的中药复方制剂的应用，其特征在于：本中药复方应用于以下方面：
中药复方制剂在制备防治急性酒精中毒药物中的应用；
中药复方制剂在制备防治慢性性酒精中毒药物中的应用；
中药复方制剂在制备防治慢性酒精中毒性脂肪肝药物中的应用；
中药复方制剂在制备治疗慢性酒精中毒导致神经中毒药物中的应用；
中药复方制剂在制备预防治疗高血脂药物中的应用；
中药复方制剂在制备预防治疗脂肪肝药物中的应用；
中药复方制剂在制备治疗肥胖中的应用；
中药复方制剂在制备降低体重中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110756154.3A CN115569164A (zh) | 2021-07-05 | 2021-07-05 | 一种解酒降脂的中药复方制剂及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110756154.3A CN115569164A (zh) | 2021-07-05 | 2021-07-05 | 一种解酒降脂的中药复方制剂及其制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115569164A true CN115569164A (zh) | 2023-01-06 |
Family
ID=84579430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110756154.3A Pending CN115569164A (zh) | 2021-07-05 | 2021-07-05 | 一种解酒降脂的中药复方制剂及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115569164A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548144A (zh) * | 2003-05-21 | 2004-11-24 | 勇 舒 | 解酒制剂及制备方法 |
| CN110882312A (zh) * | 2019-11-28 | 2020-03-17 | 东莞市东阳光健康食品有限公司 | 一种具有解酒功能的组合物及其制备方法与应用 |
| CN112616976A (zh) * | 2021-01-12 | 2021-04-09 | 胡雪松 | 一种醒酒护肝降血脂血糖草本药茶 |
-
2021
- 2021-07-05 CN CN202110756154.3A patent/CN115569164A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548144A (zh) * | 2003-05-21 | 2004-11-24 | 勇 舒 | 解酒制剂及制备方法 |
| CN110882312A (zh) * | 2019-11-28 | 2020-03-17 | 东莞市东阳光健康食品有限公司 | 一种具有解酒功能的组合物及其制备方法与应用 |
| CN112616976A (zh) * | 2021-01-12 | 2021-04-09 | 胡雪松 | 一种醒酒护肝降血脂血糖草本药茶 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (zh) | 一种具有降血糖降血脂作用的组合物 | |
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN101011562B (zh) | 参芪温胆汤新剂型及其生产方法 | |
| CN109619329A (zh) | 一种黄芪组合物及由其制备的黄芪饮料及其制备方法 | |
| CN101129485A (zh) | 石苇通淋饮料 | |
| CN101172155A (zh) | 生脉温胆汤新剂型及其生产方法 | |
| CN105878812B (zh) | 以金花茶-石斛为原料的解酒饮料及其生产方法 | |
| CN104115960A (zh) | 一种鲜芦根凉茶饮料 | |
| CN101254263A (zh) | 复方瓜子金口服液及其制备方法 | |
| CN108969591A (zh) | 一种净化血液的制剂 | |
| CN115569164A (zh) | 一种解酒降脂的中药复方制剂及其制备方法与应用 | |
| CN108686126B (zh) | 一种护肝解酒组方及制备与应用 | |
| CN101745042B (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
| CN114404517A (zh) | 一种用于痛风和降低尿酸的组合物及其用途与制备方法 | |
| CN100551424C (zh) | 一种用于解酒醒酒的中药组合物 | |
| CN108379500B (zh) | 一种养肝解酒醒酒防口臭的麦苗中药组合物及制备方法 | |
| CN113679753A (zh) | 一种调节血脂血压、提高免疫能力的口服泡腾片及其制备方法 | |
| CN102846720B (zh) | 一种降血脂、提高缺氧耐受力的组合物 | |
| CN105477500A (zh) | 一种调节婴幼儿肠胃功能的中药组合物及其制备方法和制剂 | |
| KR101330687B1 (ko) | 한약재의 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 조성물 | |
| CN102599312B (zh) | 低聚糖三七甜茶及其制备方法 | |
| KR20120113170A (ko) | 치주질환의 예방 및 개선용 조성물 | |
| CN105031033B (zh) | 一种含有枸杞叶的降血糖药物组合物及其制备方法和用途 | |
| CN115607629B (zh) | 一种具有保肝解酒的中药组合物及其制备方法 | |
| NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230106 |